COMMUNIQUÉS West-GlobeNewswire

Quanta Therapeutics Announces Presentation of QTX3034 Clinical Combination Data with Anti-EGFR and Chemotherapy in Colorectal Cancer (CRC) at ESMO and Fast Track Designation for Patients with KRAS G12D Mutations
19/10/2026
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS- [...]
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
19/10/2026
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
TLC590 Achieves Statistically Significant Reductions in Pain and Opioid Use Versus Both Placebo and Liposomal Bupivacaine in Pivotal Phase 3 Trial
19/10/2026
Met Primary Endpoint: Significant pain reduction through 72 hours vs. placebo. Significantly Reduced Opioid Use: Outperformed both placebo and liposomal bupivacaine head-to-head in pain reduction and opioid consumption [...]
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
19/10/2026
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc [...]
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
19/10/2026
VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Transactions under Novonesis’ share buyback program
19/10/2026
Please read the announcement in PDF Attachment 2026_22_Share_buyback
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/10/2026
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Prime Minister Mark Carney Sends Greetings as Canada Lights Up Sea-foam Green for International Stuttering Awareness Day
19/10/2026
From Niagara Falls to the CN Tower, landmarks across Canada will shine sea-foam green on October 22 as Canadians call for greater understanding and acceptance of stuttering. TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
19/10/2026
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedented two-year data from the trial including a 75% Objective Response [...]
RAMSAY GENERALE DE SANTE : Availability of the 2026 URD - Evolution in the Governance - Annual General meeting on 4th December 2026
19/10/2026
PRESS RELEASE Paris, 19 October 2026 EVOLUTION IN THE GOVERNANCE OF RAMSAY GENERALE DE SANTE AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT ANNUAL GENERAL MEETING ON 4 DECEMBER 2026 Ramsay Health Care Limited [...]
RAMSAY GENERALE DE SANTE : Evolution de la gouvernance - Mise à disposition du DEU 2026 - Assemblée Générale du 4 décembre 2026
19/10/2026
COMMUNIQUÉ DE PRESSE Paris, le 19 octobre 2026 EVOLUTION DE LA GOUVERNANCE DE RAMSAY GENERALE DE SANTE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2026 ASSEMBLEE GENERALE DU 4 DECEMBRE 2026 Il est rappelé [...]
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
19/10/2026
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. [...]
Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO
19/10/2026
Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing [...]
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
19/10/2026
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: [...]
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
19/10/2026
The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, [...]
Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix
19/10/2026
La joint-venture entre IBA et Framatome s’appuiera sur les capacités de Telix afin d’accélérer la production et la disponibilité de l’astate-211 sur le marché américain. Louvain-la-Neuve, Belgique, Paris, France, [...]
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
19/10/2026
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid OSE Immunotherapeutics to host a KOL webcast on [...]
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique
19/10/2026
Les résultats de Topline seront présentés par le Pr Federico Cappuzzo, PhD, le 25 octobre 2026 au congrès annuel de l’ European Society for Medical Oncology (ESMO) à Madrid OSE Immunotherapeutics organisera un webcast [...]
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
19/10/2026
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 ( 211 At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term [...]

Pages